Trial Profile
A Pilot Study Using Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Blood mononuclear cell therapy (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary) ; Ipilimumab; Nivolumab
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 12 Nov 2021 Planned initiation date changed from 1 Feb 2020 to 15 Aug 2020.
- 12 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Jan 2020 New trial record